

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended) An angiogenesis inhibitor containing rifampicin ~~an ansamycin antibiotic~~ or a pharmacologically acceptable derivative thereof as an active ingredient, wherein angiogenesis in a malignant tumor is inhibited.
2. (Currently amended) The angiogenesis inhibitor according to claim 1, wherein the pharmacologically acceptable derivative of ansamycin antibiotic is rifampicin ~~[[.]]~~ is rifamycin SV or 3-formyl rifamycin.
3. (Previously presented) The angiogenesis inhibitor according to claim 1, wherein the pharmacologically acceptable derivative is a pharmacologically acceptable salt or a hydrate thereof.
4. (Cancelled)
5. (Withdrawn) The angiogenesis inhibitor according to claim 1, wherein angiogenesis in diabetic retinopathy is inhibited.
6. (Withdrawn) The angiogenesis inhibitor according to claim 1, wherein angiogenesis in retinal angiogenesis is inhibited.
7. (Withdrawn) The angiogenesis inhibitor according to claim 1, wherein angiogenesis in an inflammatory disease is inhibited.
8. (Withdrawn) The angiogenesis inhibitor according to claim 1, wherein angiogenesis accompanying cardiovascular remodeling is inhibited.

9. (Withdrawn) A method for screening an angiogenesis-inhibiting substance wherein a test substance is added to cultured vascular endothelial cells, and an angiogenesis -inhibiting signal based on gene expression level is detected.
10. (Withdrawn) The method for screening an angiogenesis-inhibiting substance according to claim 9, wherein the angiogenesis-inhibiting signal based on reduced gene expression level in a cultured cell line is similar to the change induced by endostatin at a concentration showing a tumor regression effect.
11. (Withdrawn) The method for screening an angiogenesis-inhibiting substance according to claim 9, wherein the angiogenesis-inhibiting signal based on reduced gene expression level in a cultured cell line consists of one or more of an immediate early response gene or a related gene thereof, a growth/cell-cycle-related gene, a cell adhesion factor, a vasoactive factor, and a vasoactive factor receptor gene expressed in a vascular endothelial cell.
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Withdrawn) The angiogenesis inhibitor according to claim 2, wherein angiogenesis in diabetic retinopathy is inhibited.
16. (Withdrawn) The angiogenesis inhibitor according to claim 12, wherein angiogenesis in diabetic retinopathy is inhibited.
17. (Withdrawn) The angiogenesis inhibitor according to claim 2, wherein angiogenesis in retinal angiogenesis is inhibited.
18. (Withdrawn) The angiogenesis inhibitor according to claim 12, wherein angiogenesis in retinal angiogenesis is inhibited.

19. (Withdrawn) The angiogenesis inhibitor according to claim 2, wherein angiogenesis in an inflammatory disease is inhibited.
20. (Withdrawn) The angiogenesis inhibitor according to claim 12, wherein angiogenesis in an inflammatory disease is inhibited.
21. (Withdrawn) The angiogenesis inhibitor according to claim 2, wherein angiogenesis accompanying cardiovascular remodeling is inhibited.
22. (Withdrawn) The angiogenesis inhibitor according to claim 12, wherein angiogenesis accompanying cardiovascular remodeling is inhibited.
23. (Withdrawn) The method for screening an angiogenesis-inhibiting substance according to claim 10, wherein the angiogenesis-inhibiting signal based on reduced gene expression level in a cultured cell line consists of one or more of an immediate early response gene or a related gene thereof, a growth/cell-cycle-related gene, a cell adhesion factor, a vasoactive factor, and a vasoactive factor receptor gene expressed in a vascular endothelial cell.
24. (Cancelled)